NEURO-INFRASTRUCTURE // COGNITIVE ROI RADIUS
Invasive brain-computer interface has crossed from theory into surgical reality — but strictly as medical restoration, not enhancement. As of 2026, Neuralink reports 26 implanted participants across the PRIME (motor) and VOICE (speech) studies, with expansion into the UK, UAE and Canada and a stated record of zero serious device-related adverse events. The accessible layer for a non-pathological operator remains non-invasive EEG: focus and attention telemetry, not cortical control.
There are two distinct neural vectors, and conflating them is the category error of the entire space. Layer one is the invasive brain-computer interface — surgical, clinical, built to restore lost function. Layer two is the non-invasive operator layer — EEG telemetry and low-current stimulation, available now, built for measurement and modest training.
One restores agency to the paralyzed. The other converts 'focus' from a feeling into a signal you can track and train against. Neither, as of 2026, has been shown to add raw capability to an already-healthy brain. This dossier holds that line.
Invasive BCI — The Clinical FrontierTIER A (RESTORATION)
Neuralink's PRIME study reached 21 participants (January 2026), spanning quadriplegia from cervical spinal-cord injury and ALS. The N1 implant (1,024 electrodes) sits in the motor cortex. Participant P-18 (Jon L. Noble) reported seamless control of a MacBook by thought within weeks. A separate VOICE trial is decoding neural signals into phonemes → real-time synthesized speech for patients with severe communication impairment. Neuralink reports zero serious device-related adverse events to date.
Every implant to date restores a function that was lost — it does not enhance one that is intact. There is no peer-reviewed evidence that invasive BCI raises cognition in a healthy operator. 'Neural enhancement' as a consumer promise is, as of 2026, entirely unvetted.
Implantable BCI is clinical-trial only — restoration of agency for the paralyzed, not an elective upgrade for the intact. Restoration ≠ enhancement. Treat any pitch that blurs the two as marketing, not science.
The Operator Layer — Non-InvasiveCONSUMER / TIER B
Dry-electrode consumer EEG converts attention and focus into a tracked signal and supports neurofeedback training of focus baselines. This is measurement, not cortical control. It is a legitimate telemetry tool — it turns a subjective state into a number you can train against. Enhancement claims beyond that remain aspirational.
A 2024 meta-analysis (6 RCTs, 323 participants) found transcranial direct-current stimulation combined with cognitive training significantly improved working memory in healthy older adults — at 2 mA, across 10 or more sessions. The effect is real but modest, dose-dependent, and best-evidenced in aging populations paired with training.
Robust enhancement in young, healthy, high-performing operators is not established. Most positive signals come from older adults or are inseparable from the training they are paired with. Home-device marketing consistently outruns the evidence.
The frontier promise is cognitive enhancement. The evidence does not answer with a yes or a no — it answers by population. Who you are decides what the data supports.
tDCS paired with cognitive training produced statistically significant working-memory gains in healthy older adults (2024 meta-analysis, 6 RCTs, 323 participants). Real, dose-dependent, and modest — strongest at 2 mA over 10+ sessions.
tDCS + training meta-analysis — Front. Aging Neurosci. (2024) ↗Enhancement in already-high performers lacks robust RCT support; documented effects are inconsistent and small. The population most targeted by marketing is the one with the weakest evidence.
Neuralink PRIME/VOICE — clinical restoration only ↗EEG reliably tracks attention and supports focus training. It raises awareness of a state — it does not raise raw capability. A tracked signal is the deliverable, not a cognitive overclock.
Consumer EEG — attention telemetry (operator-accessible) ↗The honest read: stimulation and neurofeedback are measurement and modest-training tools, strongest in aging or deficit populations. For the healthy operator, today's yield is a tracked signal and a small, training-dependent edge — not a cognitive overclock. OCCABUZZ grades clinical restoration at high confidence and enhancement-in-healthy as unproven. Calibration over certainty.
The neural asset is not upgraded by a gadget — it is measured, trained, and, when damaged, restored. The operator who tracks focus as a signal and trains against it compounds a real but modest edge. The one who buys 'brain enhancement' on a marketing promise buys the promise, not the outcome. Restoration is here now. Enhancement is a projection — and OCCABUZZ will grade it the moment the human RCTs land, not before.